Torthaí cuardaigh - Hamza Hashmi

Beachtaigh na torthaí
  1. 1
    Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy

    Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy de réir James A. Davis, Douglas W. Sborov, William Wesson, Kelley Julian, Al‐Ola Abdallah, Joseph P. McGuirk, Nausheen Ahmed, Hamza Hashmi

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy

    Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy de réir Hamza Hashmi, Christina A. Bachmeier, Julio C. Chávez, Jinming Song, Mohammad Hussaini, Gabriel Krivenko, Taiga Nishihori, Hiroshi Kotani, Marco L. Davila, Frederick L. Locke, Michael D. Jain

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies

    Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies de réir James A. Davis, Katelynn Granger, Kiera Roubal, Deidra Smith, Kelly J Gaffney, Mary McGann, Alyssa Cendagorta, Aswani Thurlapati, Amanda Herbst, Lindsey Hendrickson, Hamza Hashmi, Brian T. Hess

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

    Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma de réir James A. Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P. McGuirk, Xuefei Jia, Shahzad Raza, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma de réir Danai Dima, James A. Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

    Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy de réir Olalekan O. Oluwole, Bhagirathbhai Dholaria, Tristan Knight, Tania Jain, Frederick L. Locke, Linda Ramsdell, Sarah Nikiforow, Hamza Hashmi, Kathy Mooney, Shakthi Bhaskar, Katrina Morris, Katie S. Gatwood, Brittney Baer, Larry D. Anderson, Mehdi Hamadani

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world multicentre study

    Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world mul... de réir Danai Dima, Aliya Rashid, James A. Davis, Leyla Shune, Al‐Ola Abdallah, Hong Li, Shaun DeJarnette, Jack Khouri, Louis Williams, Hamza Hashmi, Shahzad Raza, Joseph P. McGuirk, Faiz Anwer, Nausheen Ahmed

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

    Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma de réir Hamza Hashmi, Abu‐Sayeef Mirza, Alicia Darwin, Constantine Logothetis, Franco Garcia, Anuhya Kommalapati, Rahul Mhaskar, Christina A. Bachmeier, Julio C. Chávez, Bijal Shah, Javier Pinilla‐Ibarz, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Marco L. Davila, Frederick L. Locke, Taiga Nishihori, Michael D. Jain

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy de réir Danai Dima, Al‐Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis O. Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma de réir William Wesson, Danai Dima, Nahid Suleman, M Saif, Carine Tabak, Emerson Logan, James A. Davis, Mary McGann, Fateeha Furqan, Meera Mohan, Aliya Rashid, Al‐Ola Abdallah, Fauzia Ullah, Leyla Shune, Muhammad Umair Mushtaq, Shahzad Raza, Joseph P. McGuirk, Mehdi Hamadani, Faiz Anwer, Hamza Hashmi, Nausheen Ahmed

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

    Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma de réir Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Michael Heim, Ruta Brazauskas, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie Harrison, Amani Kitali, Abu‐Sayeef Mirza, Jinalben Patel, Pallavi Patwardhan, Saad Z. Usmani, Krina K. Patel, Siddhartha Ganguly, Marcelo C. Pasquini

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

    Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium de réir Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Christelle Colin, Leyla Shune, Alexandria M Shrewsbury, Rebecca Gonzalez, Douglas W. Sborov, Charlotte B Wagner, Danai Dima, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher Ferreri, Aimaz Afrough, Ankit Kansagra, Peter M. Voorhees, Rachid Baz, Jack Khouri, Melissa Alsina, Joseph P. McGuirk, Frederick L. Locke, Krina K. Patel

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

    Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis de réir Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Matthew Bye, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie J. Harrison, Amani Kitali, Heather Landau, Abu‐Sayeef Mirza, Pallavi Patwardhan, Muzaffar H. Qazilbash, Saad Z. Usmani, Krina K. Patel, Taiga Nishihori, Siddhartha Ganguly, Marcelo C. Pasquini

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience

    Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortiu... de réir Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castañeda Puglianini, Ciara L. Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James A. Davis, Charlotte B Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson, Aimaz Afrough, Danai Dima, Jack Khouri, Joseph P. McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, Melissa Alsina

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel de réir Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castañeda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan M. Herr, Hamza Hashmi, Peter A. Forsberg, Douglas W. Sborov, Larry Anderson, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji Kumar, Doris K. Hansen

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

    Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study de réir Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian T. Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma, Romil Patel, Loretta J. Nastoupil, Sairah Ahmed, Reem Karmali

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy de réir Christopher Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, Leyla Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B Wagner, Mehmet H. Kocoglu, Aaron P. Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Castañeda Puglianini

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

    Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment de réir Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter M. Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David B. Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara L. Freeman, Melissa Alsina, Frederick L. Locke, Rebecca Gonzalez, Yi Lin, Joseph P. McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

    Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myelom... de réir Nico Gagelmann, Danai Dima, Maximilian Merz, Hamza Hashmi, Nausheen Ahmed, Natalia Tovar, Aina Oliver‐Cáldes, Friedrich Stölzel, Kristin Rathje, Luise Fischer, Patrick Born, Lisa Schäfer, Anca‐Maria Albici, Natalie Schub, Shlomit Kfir‐Erenfeld, Miri Assayag, Nathalie Asherie, Gerald Wulf, Soraya Kharboutli, Fabian Müller, Leyla Shune, James A. Davis, Faiz Anwer, Vladan Vučinić, Uwe Platzbecker, Francis Ayuk, Nicolaus Kröger, Jack Khouri, Carmelo Gurnari, Joseph P. McGuirk, Polina Stepensky, Al‐Ola Abdallah, Carlos Fernández de Larrea

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium de réir Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castañeda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: